

US\$0.63bn Market Cap. 94.37% Free Float US\$4.10mn Avg. Daily Value traded

Research Department  
Madhu Appissa, CFA  
Tel +966 11 836 5464, appissam@alrajhi-capital.com

## Neutral

Price Target (SAR): 25.3

Current: 27.7  
Upside/Downside: 8.8% below current

Valuation Multiples	23	24E	25E
P/E (x)	15.9	22.3	21.5
P/B (x)	1.9	1.9	1.7
ROE (%)	12.4	10.0	8.3

## Major Shareholders % Ownership

Saudi Awwal Bank	15.60
------------------	-------

Price Performance	1M	3M	YTD
Absolute	23.5%	43.8%	46.1%
Relative to TASI	21.9%	40.6%	42.3%

## Earnings

	2023	2024E	2025E
<b>GWP</b>	3,346	3,747	4,127
<i>Growth</i>	27%	12%	10%
<b>Insurance Revenue</b>	2,888	3,413	3,692
<b>Insurance Expenses</b>	(1,679)	(2,052)	(2,248)
<b>Reinsurance Income/Expenses</b>	(1,180)	(1,310)	(1,368)
<b>Insurance service result</b>	28	51	76
<i>Growth</i>	NM	83%	48%
<b>Net insurance and investment results</b>	189	219	238
<i>Growth</i>	NM	16%	8%
<b>Profit Before Tax</b>	163	179	194
<i>Growth</i>	NM	10%	8%
<b>Net Profit</b>	148	159	165
<i>Growth</i>	NM	7%	4%
<b>ROE</b>	12.4%	10.0%	8.3%
<b>P/E</b>	15.9x	22.3x	21.5x
<b>P/B</b>	1.9x	1.9x	1.7x

Source: Company data, Al Rajhi Capital

# Walaa Cooperative Insurance Co.

## Turn neutral; profits to improve, but rights issue to weigh on ROE


Walaa's Q4 2023 earnings were better than our expectations, supported by strong insurance revenues and investment income. The surprise in insurance revenue (+12%) came mainly from the motor insurance business. The GWP growth (+37% in Q4 and +27% in FY 2023) also was very solid led by the motor business (+217% y-o-y in Q4). However, core insurance results were slightly disappointing as despite the growth in the topline, the core insurance results were just about SAR 6.0mn hurt by continued deterioration in the medical portfolio. The insurance service expense in medical was over 130% of the revenue in Q4 2023, the negative impact of this was offset by motor business to some extent. The company is investing to build capabilities in the medical business to become one of the leading players in the medical segment, thus the expenses could stay elevated in the near future. Moreover, high claims witnessed across the industry in Q4 2023 weighed on the medical portfolio performance. From a medium to longer term point of view, the current investments in building in-house claim management should help the company to become a leading player in the growing medical insurance business.

The motor insurance business was a major surprise in Q4 2023, despite the sharp growth in the motor revenues, the insurance service expense ratio improved notably to about 90% in Q4 2023 from 108% in Q3 2023. In addition to solid topline growth, this could be due to the possibility of reversal of some of the loss component booked for onerous contracts in the recent past (last 4-6 quarters motor insurance exp. was elevated). Nevertheless, the improvement was solid compared to Q4 2022's expense ratio of 136%. Going forward in 2024, some improvement in the expense ratio in the motor is expected, but we remain skeptical and would not assume the business to turn notably profitable in 2024 as we have observed erosion in price discipline and rise in accidents. Further, the company's motor portfolio is skewed towards TPL product, where the loss ratio is the highest among the products.

In our view, investment income will continue to be solid and should support profitability in 2024. Further, some improvement in the medical and motor should also reduce the losses and improve the profitability. We estimate insurance revenues to grow by 18% y-o-y and bottom-line to grow by 7% y-o-y in 2024. In terms of concerns, we are worried about the notable dilution the rights issue can cause and it would weigh on the return on equity. The company's plan is to issue rights shares of SAR 467.5mn at a price of SAR 11/share, which is a notable discount to the current market price of SAR 27.7/share. The rights issue will add 42.5mn shares to its existing outstanding shares of 85.1mn, that is a notable dilution, in our view.

**Valuations:** The insurance industry is witnessing strong growth in the non-medical segments and the prospects are also solid for these segments, particularly in general insurance such as property & casualty, engineering, etc. The company's decision to raise capital should help to capture the market share in this growing segment. Further, the ongoing investments in the medical business should help the company to grab some market share from its peers in the medium term. As the growth prospects appear bright, we raise our target price to book multiple to 1.7x, but still at a notable discount to Rajhi and Tawuniya's multiples of 6.4x. Despite the strong growth, the reason for discount to peers such as Al Rajhi Takaful is mainly on concerns around the ROE levels. The decision to issue rights shares at such a steep discount will weigh on return on equity and offset the improvement coming from the operational performance. We estimate return on equity to hover around 8%-10% in the medium term, much lower than key peers ROEs of 18%-20% (Al Rajhi Takaful and Tawuniya). Based on 1.7x price to book applied on 2024 book value per share of SAR 14.9, our new target price is SAR 25.3/share, that indicates a downside of 8.8% from the current levels and implies Neutral rating on the stock.

Figure 1 Walaa trading near all-time high



Source: Company Data, Al Rajhi Capital

Figure 2 Valuations

Relative Valuation	Value
P/B Multiple	1.7x
2024E BVPS	14.9
<b>Target Price</b>	<b>25.3</b>
CMP	27.7
Upside/Downside	-8.8%

Source: Company Data, Al Rajhi Capital

## Financials

Figure 3 Income Statement

	2023	2024E	2025E	2026E
<b>GWP</b>	<b>3,346</b>	<b>3,747</b>	<b>4,127</b>	<b>4,497</b>
<i>Growth</i>	27%	12%	10%	9%
Insurance Revenue	2,888	3,413	3,692	4,009
<i>as % of GWP</i>	86%	91%	89%	89%
Insurance Expenses	(1,679)	(2,052)	(2,248)	(2,442)
Reinsurance Income/Expenses	(1,180)	(1,310)	(1,368)	(1,475)
<b>Insurance service result</b>	<b>28</b>	<b>51</b>	<b>76</b>	<b>92</b>
<i>Growth</i>	NM	83%	48%	21%
Investment Income & Finance Expenses	161	168	162	149
<b>Net insurance and investment results</b>	<b>189</b>	<b>219</b>	<b>238</b>	<b>241</b>
Other operating expenses	(37)	(44)	(48)	(52)
Other Income	11	3	4	4
<b>Profit Before Tax</b>	<b>163</b>	<b>179</b>	<b>194</b>	<b>193</b>
<i>Growth</i>	NM	10%	8%	0%
Zakat & taxes	(15)	(20)	(29)	(29)
<b>Net Profit</b>	<b>148</b>	<b>159</b>	<b>165</b>	<b>164</b>
<i>Growth</i>	NM	7%	4%	0%

Source: Al Rajhi Capital estimates

Figure 5 Drivers

		2023	2024E	2025E	2026E
Medical	GWP	680	761	837	921
	Insurance Revenue	668	745	820	902
	Expense ratio	109%	103%	101%	100%
Energy	GWP	578	584	595	607
	Insurance Revenue	634	633	643	656
	Expense ratio	5%	8%	10%	10%
Motor	GWP	795	898	988	1,067
	Insurance Revenue	513	725	810	875
	Expense ratio	103%	100%	99%	98%
Engineering	GWP	245	306	367	422
	Insurance Revenue	178	245	294	338
	Expense ratio	35%	35%	35%	35%
P&C	GWP	299	374	448	515
	Insurance Revenue	223	280	336	387
	Expense ratio	17%	25%	25%	25%
P&S	GWP	284	312	344	378
	Insurance Revenue	227	243	268	295
	Expense ratio	74%	70%	70%	70%
Others	GWP	465	512	548	586
	Insurance Revenue	445	541	520	557
	Expense ratio	28%	35%	35%	35%

Source: Al Rajhi Capital estimates

Figure 4 Balance sheet

	2023	2024E	2025E	2026E
Statutory deposit	85	85	85	85
Property and equipment, net	35	34	34	34
Investments	1,655	1,739	1,828	1,921
Deposits	776	776	776	776
Prepaid expenses and other assets	53	53	53	53
Reinsurance contract assets	790	738	717	693
Goodwill & Intangibles	146	145	145	144
Cash and cash equivalents	512	875	863	850
Others	55	55	55	55
<b>Total Assets</b>	<b>4,107</b>	<b>4,501</b>	<b>4,556</b>	<b>4,611</b>
Accrued expenses and other liabilities	170	177	194	210
Insurance contract liabilities	2,555	2,311	2,179	2,048
Others	114	118	124	129
<b>Total Liabilities</b>	<b>2,839</b>	<b>2,606</b>	<b>2,496</b>	<b>2,387</b>
<b>Total Equity</b>	<b>1,268</b>	<b>1,895</b>	<b>2,059</b>	<b>2,223</b>
<b>Total Liabilities &amp; Equity</b>	<b>4,107</b>	<b>4,501</b>	<b>4,556</b>	<b>4,611</b>

Source: Al Rajhi Capital estimates

## IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

### Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report.

Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Rajhi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Rajhi.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

## Disclaimer and additional disclosures for Equity Research

### Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

### Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

### Contact us

**Mazen AlSudairi, CFA**  
Head of Research  
Tel : +966 11 836 5468  
Email: [alsudairim@alrajhi-capital.com](mailto:alsudairim@alrajhi-capital.com)

**Al Rajhi Capital**  
Research Department  
Head Office, King Fahad Road  
P.O. Box 5561, Riyadh 11432  
Kingdom of Saudi Arabia  
Email: [research@alrajhi-capital.com](mailto:research@alrajhi-capital.com)

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37